chrisvoncsefalvay/vaers-outcomes huggingface dataset:
On 8/21, approximately 24 hours after shot, began to feel very fatigued, ran low temp, felt a bit achy all over; both eyes were achy and became bloodshot, irritated.  On 8/22, woke up and those symptoms were gone but noticed around 10:00 AM that lymph node near left collar bone was sore and swollen (shot given in left arm).  On 8/23, lymph node more swollen and more soreness, also experiencing a little itchiness in lower neck, upper chest.  Also, I forgot to list that I took a 200mg Naproxen Sodium gel capsule after retuning home on 8/20, from getting the shot (Pharmacist said it would be fine to do so), as preemptive measure to possible side effects.  I also took one the next morning, 8/21.  Have not taken another since.
Horrible migraine; nausea; sore arm; This is a spontaneous report from a contactable consumer, the patient. A 20-year-old non pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9263) via an unspecified route of administration in left arm on 26Feb2021 at 11:00 (at the age of 20-years-old) as a single dose for COVID-19 immunisation. The patient's medical history was not reported.  Concomitant medications were not reported. The patient had a drug allergy to amoxicillin. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 26Feb2021 at 17:00, the patient had experienced horrible migraine, nausea and sore arm. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit emergency room/department or urgent care. No therapeutic measures were taken as a result of adverse events. The clinical outcome of the events, horrible migraine, nausea and sore arm was recovered on an unknown date in 2021.   No follow-up attempts are needed. No further information is expected.
This spontaneous report as received from a registered nurse refers to a male patient of unknown age. The patient had fainted after receiving a dose of GARDASIL (lot number, therapy route and site not reported). Date or information for the male patient that fainted was unspecified. The outcome was unknown. Upon internal review, fainted was considered to be a medically significant event. The nurse also reported a second male patient had had passed out after receiving a dose of GARDASIL on 24-JUL-2012 (MARRS # 1207USA009538). Additional information has been requested.
broke out with bumps everywhere; bumps from the tip of the shoulder to the injection site; rash; red bumps from the tip of the shoulder to the injection site; This spontaneous case was reported by a consumer and describes the occurrence of SKIN MASS (broke out with bumps everywhere), VACCINATION SITE MASS (bumps from the tip of the shoulder to the injection site), RASH (rash) and VACCINATION SITE ERYTHEMA (red bumps from the tip of the shoulder to the injection site) in a 63-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Thyroid disorder (it was reported as not clear whether hyperthyroidism or hypothyroidism,  also mentioned Hajimoto's disease.), Heart attack (Reported as twice almost has a heart attack.), Allergy multiple (reported as allergic to everything), Adhesive tape allergy (reported as allergic to band-aids), Eczema and Hashimoto's disease. Concomitant products included ASPIRIN [ACETYLSALICYLIC ACID] for an unknown indication.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced SKIN MASS (broke out with bumps everywhere), VACCINATION SITE MASS (bumps from the tip of the shoulder to the injection site), RASH (rash) and VACCINATION SITE ERYTHEMA (red bumps from the tip of the shoulder to the injection site). At the time of the report, SKIN MASS (broke out with bumps everywhere), VACCINATION SITE MASS (bumps from the tip of the shoulder to the injection site), RASH (rash) and VACCINATION SITE ERYTHEMA (red bumps from the tip of the shoulder to the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No treatment medications were provided.   This case was linked to MOD-2021-286389 (Patient Link).
on and off complaints of headache with recurrent low grade fever since last night. Had diarrhea yesterday afternoon.
Suspected urticarial vasculitis. Started about 7 hours after first vaccine, now persisitng 2 months later. Has rheum follow up pending.
1:00pm 4-28-11 pt. states had onset of nausea and dizziness. Also, 4th finger (pointer finger) with redness and swelling. Then 7:30pm on 4-28-11 noted redness and swelling of 1st finger (pinky finger). 4-29-11 9:15AM nausea, dizziness resolved. States swelling & redness decreased to 1st & 4th finger.
After the shot my left arm became sore and tender. Later my arm had pain from my elbow radiating up into my neck and head causing a massive headache on the left side of my head. I had chills with NO fever. I felt nauseated. I went to work the following day with all of the previous symptoms. I experienced sweats along with the chilling and light headed ness. I started to experience tachycardia. My supervisor on my floor took my blood pressure and it was 164/122 and my pulse rate was 190. A PA was available and examined me and asked if I had caffeine which I didn?t. After sitting and being re-examined my blood pressure was 142/100, and my pulse was 90. I was sent home. At home I still experienced the headache and was fatigued, and my arm was still sore and tender. This happened within 24-25 hours after receiving the vaccine. Today my arm is slightly sore and I still have a headache but it is not as severe as previous.
Patient describes of having persistent chest pain (pressure) and SOB that has started 1 month prior shortly after receiving her booster of Moderna vaccine.
pt recv vax & devel an inj site rxn which persisted for more than 1 wk & was characterized by tenderness, redness & swelling;
Prolonged high pitched crying episodes onset 2 days after shots given. Tylenol ineffective. Continued through 4/21/08
Burning sensation on the injection site, dizzy and mild blurry vision.  BP 130/84, HR - 84
Developed persistent urticaria, skin flaking, hives not relieved by multiple antihistamines. Treated with long term prednisone taper
Redness, some darker red in the middle, mild itching,  induration. PCP describes as possible necrosis
sharp chest pains for the last 2 weeks; This is a spontaneous report from a contactable consumer or other non hcp. The consumer (patient) reported for herself. A 33-years-old female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, Solution for injection, Batch/Lot Number: ER8731), via an unspecified route of administration, administered in Arm Right on 20Apr2021 10:20 (at the age of 33-years-old) as dose 1, single for covid-19 immunisation. The medical history and concomitant medications. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient had no AE(s) following prior vaccinations. The patient had no Medical History (Including any illness at time of vaccination). The patient had no family medical history relevant to AE. The patient had no history of previous immunizations with the Pfizer vaccine considered as suspect. On 23Apr2021 the patient experienced sharp chest pain for the last 2 weeks. The patient reported sharp chest pains for the last 2 weeks and came in waves. The patient reported that she had a side effect after the first dose of the vaccine. Should she get the second dose as today is the day for the second dose, if this is a normal side effect should she hold off another week. The patient reported that it was reported a 22-year-old woman and a 33-year-old man died due to heart inflammation following the vaccine. This was in Israel, not in the US. The reporter stated that she is coming up on her second dose and since the first dose she has been having chest pains. States that she tried to Google search to see if this was a normal symptoms after the vaccine but could not find anything. She asked if it is normal and has anyone else reported the same. She reported that the pains started 3 days after her shot and it has been just sharp pains throughout her chest for about 2 weeks and the pains continue to persist she is a healthy 33 year old female. The patient Denied any medical conditions, medications, labs, testing, or treatments relevant to event. The patient was informed that she should not get the Pfizer-BioNTech COVID-19 Vaccine if she had a severe allergic reaction after a previous dose of the vaccine or if she had a severe allergic reaction to any ingredient of the vaccine. The decision to receive the second dose for any other reason cannot be made by Pfizer and was referred to speak to her healthcare provider about the risks of the vaccine compared to the risks of potentially not being fully protected against COVID-19 infection. The outcome of the event was not resolved. No follow-up attempts are possible. No further information is expected.
This spontaneous case reported by a consumer, describes the occurrence of influenza-like illness (flu-like symptoms), pyrexia (low-grade fever), myalgia (muscle pain), headache and fatigue in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 vaccine, batch# 030M20A) for COVID-19 vaccination. The occurrence of additional events detailed below. No medical history reported. On Feb 5, 2021, patient received the first dose of mRNA-1273 (Moderna COVID-19 vaccine), unknown route; 1 dosage form. On Feb 6, 2021, patient experienced influenza-like illness (flu-like symptoms), pyrexia (low-grade fever), myalgia (muscle pain), headache, fatigue, pain in extremity (pain in her arm), vaccination site erythema (red mark in injection site) and arthralgia (joint pain). On Feb 7, 2021, influenza-like illness (flu-like symptoms), pyrexia (low-grade fever) and headache resolved. On Feb 9, 2021, myalgia (muscle pain), fatigue, pain in extremity (pain in her arm) and arthralgia (joint pain) resolved. On Feb 20, 2021, vaccination site erythema (red mark in injection site) resolved. The action taken with mRNA-1273 (Moderna COVID-19 vaccine): unknown. No concomitant medications or treatment information provided.
The following day I experienced soreness at the injection site that lasted for about 5-6 days. For the first two days, I experienced fatigue. Lastly, about 2 days after the injection I developed redness at the injection site that lasted for several days.
Started 2/17/21 two days after vaccine shot.   Left arm and shoulder pain upon waking.  Intense burning sensation  across top of shoulder, down over shoulder blade and entire left arm, including hand.  Sharp pain with cramping feeling.  Difficulty finding a comfortable position because entire arm is tender, sore to the touch, as well burning feeling. Duration: 2/17/21 - still ongoing.      2 ER Visits.  2 PCP Visits
Rash at the back right hand  side of neck. Raised bumps in cluster. Very itchy and red. No pustules.  Spread, but not as severe, around  the right eye.  Individual bumps around eye with small cluster underneath the eye orb. Swollen at rash site.   Treating with chilled compress.
This spontaneous report as received from a nurse refers to a unspecified patients of unknown age and gender. In approximately 2017, reported as between 05-SEP-2017 and 26-SEP-2017, the patients were vaccinated with improperly stored doses of GARDASIL 9 (doses and anatomical locations were not reported, lot # N009801 expiration date: 10-NOV-2020, intramuscularly) for an unknown indication. Data logger involved (28.5F for 5 minutes). There was no previous temperature excursion. No adverse effects reported. This is one of several reports received from the same reporter. Additional information has been requested. Sender's Comments: US-009507513-1709USA013890.
4 days after varicella injection (L) arm swelling, itchy at vaccine site. Hives now at 7 days following injection. No lesions, no rash, no nerve or muscle changes.
tremor to right hand 2 weeks after 1st dose of Pfizer COVID 19 vaccine
10 minutes after vaccination, patient compaint of chest tightness, shortness of breath,  weakness.  Pt diaphoretic,  BP 91/52, P 50, R 26.  EpiPen 0.3 mg admnistered right thigh after 911 activated.  Pt transported to ER via ambulance in stable condition
transferred from an outside hospital  # COVID, 1st diagnosed 10/14 Likely represents continued shedding of virus.  Will touch base with facility in the morning to discuss removing isolation.
Tested positive for COVID-19 with symptoms; Tested positive for COVID-19 with symptoms; Booster; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  A 21 year-old female patient received bnt162b2 (BNT162B2), administration date 08Oct2021 (Batch/Lot number: unknown) as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "No underlying conditions/None" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (DOSE 1), for Covid-19 immunization; Bnt162b2 (DOSE 2), for Covid-19 immunization. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 09Dec2021, outcome "unknown" and all described as "Tested positive for COVID-19 with symptoms"; IMMUNISATION (non-serious) with onset 08Oct2021, outcome "unknown", described as "Booster". The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (09Dec2021) positive. It was reported that patient started with flu-like symptoms, and was tested positive for COVID-19 rapid-home test on previous night of this report. The patient had headache, runny nose, sneezing, fatigue, feeling weak, nausea, very mild cough and mild shortness of breath. The patient did not have fever.  The lot number for bnt162b2 was not provided and will be requested during follow up.
3OCT97 6PM pt states felt itchy & got a couple of hives on rt thigh;4OCT97 states took atarax & zantac;states by 6OCT97 was covered w/welts & hives;states face became swollen;6OCT97 seen by MD;meds dec hives;then hives recurring;
Experiencing what is being described as ?Covid Arm?. Redness at injection site, hard lump, feverish to touch, painful. My arm feels like dead weight and there?s a white hot burning sensation in my shoulder joint. Nausea, dizziness and light headed feeling that comes and goes.
Soreness of the arm; Real Itching; Two rashy spots around the injection site; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Soreness of the arm), PRURITUS (Real Itching) and VACCINATION SITE RASH (Two rashy spots around the injection site) in a 75-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031M20A) for COVID-19 vaccination.     Concurrent medical conditions included Blood pressure high, Diabetes and COPD.    On 08-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (Soreness of the arm), PRURITUS (Real Itching) and VACCINATION SITE RASH (Two rashy spots around the injection site). At the time of the report, PAIN IN EXTREMITY (Soreness of the arm), PRURITUS (Real Itching) and VACCINATION SITE RASH (Two rashy spots around the injection site) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
Soreness in shoulder muscle that resulted in limited mobility and weakness, lasting 2+ years. Pushups were difficult.
Dose Was Administered Too Early; Received HEPLISAV-B as Third Dose in Engerix-B Series; Initial Report Received 06-Feb-2020  A pharmacist reported that a 21-year-old female with no known drug allergies received 2 doses of Engerix-B (dose 1 date not specified, dose 2 administered on 30-Dec-2019).  On 06-Feb-2020, Heplisav-B (Lot# 933622, Expiration date 01-Aug-2021) was administered.  No additional information was provided.    Company comment: The company assessed the events as non-serious.; Sender's Comments: The company assessed the events as non-serious.
inc in achiness of body & joints p/vax;felt very tired, diff to get up in  morning;body aches & pain;
mom states that pt woke up 2AM crying, vomiting; t105 tympanic thermometer; give APAP as instructed until fever dec;
A solicited report was received from Health Professional concerning an adult, female subject enrolled in a study, who ha been receiving FLUMIST (intranasal). FLUMIST (intranasal) started on an unknown date. The patient experienced pregnant patient received LAIV3 and pharyngeal pain. The outcome of the event of pregnant patient received LAIV3 and pharyngeal pain is unknown. The reporter's description of the event(s) was as follows: There was one report of non-serious pharyngeal pain after receiving QLAIV3 during pregnancy. The report was considered to be non-serious. Based on the information in this report, and awaiting the reporter's assessment, the company physician considered the events pregnant patient received LAIV3 and pharyngeal pain with suspect drug FLUMIST to be unrelated.
CHILLS; SORE LEFT ARM; HIGH FEVER 103.9 F; HEADACHE; This spontaneous report received from a patient concerned a 26 year old male. The patient's height, and weight were not reported. The patient's concurrent conditions included non-smoker, and alcohol user, and other pre-existing medical conditions included the patient had no known drug allergies. no drug abuse or illicit drug use. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 204A21A expiry: 07-AUG-2021) dose was not reported, administered on 12-JUN-2021 for prophylactic vaccination. Concomitant medications included paracetamol/ dextromethorphan hbr /guaifenesin / pseudoephedrine hcl for fever. On 12-JUN-2021, the subject experienced chills. On 12-JUN-2021, the subject experienced sore left arm. On 12-JUN-2021, the subject experienced high fever 103.9 f. On 12-JUN-2021, the subject experienced headache. Laboratory data included: Body temperature (NR: not provided) 103.9 F. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from high fever 103.9 f, headache, chills, and sore left arm. This report was non-serious.
100.4 fever by evening of first day, chills, abdominal pain, nausea, migraine, sore throat on one side, fatigue.  Fever broke overnight; all symptoms seemed to resolve by the end of the second day.
chills/shivering; cold; couldn't sleep; sick as a dog; This is a spontaneous report received from a contactable reporter (Consumer) from medical information team. The reporter is the parent.  A 38 year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) (Batch/Lot number: unknown) as dose 2, single for covid-19 immunization. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Dose 1, MANUFACTURER UNKNOWN, (Lot number: not provided)), for covid-19 immunization. The following information was reported: CHILLS (non-serious), outcome "unknown", described as "chills/shivering"; NASOPHARYNGITIS (non-serious), outcome "unknown", described as "cold"; INSOMNIA (non-serious), outcome "unknown", described as "couldn't sleep"; ILLNESS (non-serious), outcome "unknown", described as "sick as a dog".  Additional information: Caller stated her 38 year-old son received his second Pfizer Covid vaccine dose and experienced  "a terrible reaction all night; chills, cold, shivering, couldn't sleep and was sick as a dog."   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
redness; lost his sense of taste and smell; lost his sense of taste and smell; This spontaneous case was reported by a consumer and describes the occurrence of HYPOGEUSIA (lost his sense of taste and smell), HYPOSMIA (lost his sense of taste and smell) and INJECTION SITE ERYTHEMA (redness) in a 63-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 05-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Jan-2021, the patient experienced HYPOGEUSIA (lost his sense of taste and smell) and HYPOSMIA (lost his sense of taste and smell). On an unknown date, the patient experienced INJECTION SITE ERYTHEMA (redness). At the time of the report, HYPOGEUSIA (lost his sense of taste and smell) and HYPOSMIA (lost his sense of taste and smell) had not resolved and INJECTION SITE ERYTHEMA (redness) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 18-Jan-2021, SARS-CoV-2 test: (Negative) negative. On 20-Jan-2021, SARS-CoV-2 test: (Negative) negative.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter. Treatment information was not provided.     This case was linked to MOD-2021-014303 (Patient Link).
15APR92 recvd vax; 18APR - 19APR severe "flu like" sxs i.e. aching joints, profuse sweating, no temp; 24APR sx dec but felt tired; 25APR - 26APR severe flu like sx again, in bed 2 days; 28APR "tongue red & blistered" & "burning all over";